scholarly journals Nonalcoholic fatty liver diseases as dramatic consequence of obesity

2019 ◽  
Vol 3 (20) ◽  
pp. 37-40
Author(s):  
V. A. Akhmedov
Keyword(s):  
Risk Factor ◽  
Fatty Liver ◽  
Atherogenic Dyslipidemia ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Modern Health Care ◽  
High Prevalence ◽  
Prevalence Of Obesity ◽  
Nonalcoholic Fatty Liver Diseases ◽  
Common Risk Factors

Against the backdrop of the high prevalence of obesity in the population, non-alcoholic fatty liver disease (NAFLD) is a serious problem for modern health care. NAFLD is an independent risk factor for the development of cardiovascular diseases (CVD), regardless of the presence of traditional factors. CVD and NAFLD have common risk factors, including insulin resistance (peripheral and hepatic), atherogenic dyslipidemia, and abdominal obesity. This article presents modern views on the mechanisms of CVD formation in patients with NAFLD, as well as modern methods for the diagnosis of liver fibrosis as the main risk factor for the development of cardiovascular catastrophes.

scholarly journals Laboratory diagnostics of non-alcoholic fatty liver disease

2015 ◽  
Vol 38 (2) ◽  
Author(s):  
Arnold von Eckardstein
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Laboratory Diagnostics ◽  
Health Issues ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Non Invasive ◽  
High Prevalence

AbstractOwing to the high prevalence and associated complications of liver fibrosis, of any etiology, and nonalcoholic fatty liver disease (NAFLD), both have become important public health issues. Liver biopsy is considered the gold standard for diagnosis and staging of liver fibrosis, as well as NAFLD. Recent studies have discovered and validated several non-invasive biochemical biomarkers and imaging procedures for the diagnostics of liver fibrosis and NAFLD. In comparison to patented tests (FibroTest

scholarly journals Key points of etiopathogenesis of non-alcoholic fatty liver disease

2019 ◽  
Vol 21 (2) ◽  
pp. 219-222
Author(s):  
I I Zhirkov ◽  
A V Gordienko ◽  
D Yu Serdyukov ◽  
G Yu Dorokhov
Keyword(s):  
Liver Disease ◽  
Magnetic Resonance ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Atherogenic Dyslipidemia ◽  
Resonance Spectroscopy ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Based on the analysis of Russian and foreign literature sources, the definition of non-alcoholic fatty liver disease is given, modern data on the etiology, prevalence, risk factors for the development and progression of non-alcoholic fatty liver disease are presented. Nonalcoholic fatty liver disease found in at least a quarter of the world’s population and the main target of this disease is the most able-bodied and economically active part of the population. These circumstances give this problem special medical, social and humanitarian significance. Two different pathomorphological states represent non-alcoholic fatty liver disease: nonalcoholic fatty liver and nonalcoholic steatohepatitis, which, in turn, includes liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Non-alcoholic fatty liver disease is determined not only on the basis of the results of histological studies in the presence of steatosis in more than 5% of hepatocytes, but also in excess of proton density of more than 5.6% during proton magnetic resonance spectroscopy, or when performing selective magnetic resonance imaging with quantitative determination of fat and water. Modern data on the pathogenesis of nonalcoholic fatty liver disease are presented. Attention is focused on such key mechanisms in the development of the disease as insulin resistance, lipotoxicy, oxidative stress, systemic aseptic inflammation, mitochondrial dysfunction and endoplasmic reticulum, which served as the basis of the pathogenetic theory of «multi hit». The pathogenesis of nonalcoholic fatty liver disease plays an important role visceral adipose tissue, which also synthesized proinflammatory cytokines and adipokines, as well as the syndrome of excessive bacterial growth, due to the formation of endotoxemia and atherogenic dyslipidemia.

scholarly journals Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome

2019 ◽  
Vol 2 (13) ◽  
pp. 52-56 ◽  
Author(s):  
V. A. Akhmedov ◽  
O. V. Gaus
Keyword(s):  
Metabolic Syndrome ◽  
Metabolic Disorders ◽  
Gallbladder Disease ◽  
Gallstone Disease ◽  
Atherogenic Dyslipidemia ◽  
Main Role ◽  
Alcoholic Fatty Liver ◽  
Modern Health Care ◽  
High Prevalence ◽  
Alcoholic Fatty Liver Disease

The high prevalence of metabolic syndrome in population has led to the cholelithiasis is important problem of modern health care along with coronary heart disease, arterial hypertension and diabetes. The main role in the formation of gallbladder pathology in patients with metabolic syndrome belongs to insulin resistance, atherogenic dyslipidemia, and non‑alcoholic fatty liver disease. Тhe prescription of ursodeoxycholic acid is pathogenetically justified. This article presents modern views on the mechanisms formation of gallstone disease in the conditions of metabolic disorders and management of this patients based on the results own research.

New therapy for fatty liver

2018 ◽  
Vol 1 (2) ◽  
pp. 24-28
Author(s):  
Tanita Suttichaimongkol
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Liver Insulin Resistance ◽  
Alcoholic Fatty Liver Disease ◽  
Related Mortality

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of death from liver cirrhosis, endstage liver disease, and hepatocellular carcinoma. It is also associated with increased cardiovasculardisease and cancer related mortality. While lifestyle modifications are the mainstay of treatment,only a proportion of patients are able to make due to difficult to achieve and maintain, and so moretreatment options are required such as pharmacotherapy. This review presents the drugs used inmanaging NAFLD and their pharmacologic targets. Therapies are currently directed towards improvingthe metabolic status of the liver, insulin resistance, cell oxidative stress, apoptosis, inflammation orfibrosis. Several agents are now in large clinical trials and within the next few years, the availability oftherapeutic options for NAFLD will be approved.     Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, cirrhosis  

Effect of Chinese Herbal Monomer Hairy Calycosin on Nonalcoholic Fatty Liver Rats and its Mechanism

2019 ◽  
Vol 22 (3) ◽  
pp. 194-200 ◽  
Author(s):  
Xiang Liu ◽  
Zhi-Hong Xie ◽  
Chen-Yuan Liu ◽  
Ying Zhang
Keyword(s):  
Fatty Liver ◽  
Liver Tissue ◽  
Liver Homogenate ◽  
Control Group ◽  
Necrosis Factor Alpha ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Chinese Herbal ◽  
Tnf Α ◽  
Model Control

Background: Chinese herbal monomer hairy Calycosin is a flavonoid extracted from Radix astragali. Aims and Scope: The aim of the research was to investigate the effect and mechanism of Hairy Calycosin on Non-Alcoholic Fatty Liver Dieases (NAFLD) in rats. Materials and Methods: 60 rats were randomly divided into 6 groups, then NAFLD rat models were prepared and treated with different doses of Hairy Calycosin (0.5, 1.0, 2.0 mg/kg) or Kathyle relatively. Results: Both 1.0 mg/kg and 2.0 mg/kg Hairy Calycosin treatment could significantly increase the serum Superoxide Dismutase (SOD) content of the model rats and reduce the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), Free Fatty Acid (FFA), IL-6, tumor necrosis factor-alpha (TNF-α) and liver homogenate malondialdehyde (MDA), while 2.0 mg/kg Hairy Calycosin can down-regulate liver tissue cytochrome p450 2E1 (CYP2E1). In the electron microscope, compared with the model control group, the mitochondrial swelling in the hepatocytes of Hairy Calycosin (1.0, 2.0 mg/kg) treatment group was significantly reduced, the ridge on the inner membrane of mitochondria increased, and the lipid droplets became much smaller. Conclusion: Hairy Calycosin can effectively control the lipid peroxidation in liver tissues of rats with NAFLD, and reduce the levels of serum TNF-α, IL-6, MDA and FFA, effectively improve the steatosis and inflammation of liver tissue, and down-regulate the expression of CYP2E1, inhibit apoptosis of hepatocytes.

Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease

2020 ◽  
Vol 21 (6) ◽  
pp. 599-609 ◽  
Author(s):  
Longxin Qiu ◽  
Chang Guo
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Fatty Liver ◽  
Aldose Reductase ◽  
Fatty Liver Disease ◽  
Acid Oxidation ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver

Aldose reductase (AR) has been reported to be involved in the development of nonalcoholic fatty liver disease (NAFLD). Hepatic AR is induced under hyperglycemia condition and converts excess glucose to lipogenic fructose, which contributes in part to the accumulation of fat in the liver cells of diabetes rodents. In addition, the hyperglycemia-induced AR or nutrition-induced AR causes suppression of the transcriptional activity of peroxisome proliferator-activated receptor (PPAR) α and reduced lipolysis in the liver, which also contribute to the development of NAFLD. Moreover, AR induction in non-alcoholic steatohepatitis (NASH) may aggravate oxidative stress and the expression of inflammatory cytokines in the liver. Here, we summarize the knowledge on AR inhibitors of plant origin and review the effect of some plant-derived AR inhibitors on NAFLD/NASH in rodents. Natural AR inhibitors may improve NAFLD at least in part through attenuating oxidative stress and inflammatory cytokine expression. Some of the natural AR inhibitors have been reported to attenuate hepatic steatosis through the regulation of PPARα-mediated fatty acid oxidation. In this review, we propose that the natural AR inhibitors are potential therapeutic agents for NAFLD.

Sign in / Sign up

Export Citation Format

Share Document